13D Filings
CASI Pharmaceuticals, Inc.
CASI
Amendment
Ownership

23.80%

Total Shares

3,735,535

Issuer CIK

1962738

CUSIP

G1933S101

Event Date

Jun 15, 2025

Accepted

Jun 20, 2025, 04:30 PM

Reporting Persons (6)
NameType% of ClassAggregateSole VotingShared Voting
WEI-WU HE, Ph.D.
Individual
23.80%3,735,5352,130,5501,604,985
EMERGING TECHNOLOGY PARTNERS, LLC
Other
7.10%1,097,34101,097,341
ETP Global Fund L.P.
Partnership
4.90%753,2340753,234
HUIYING MEMORIAL FOUNDATION
CO
2.60%407,6440407,644
ETP BIOHEALTH III FUND , L.P.
Partnership
1.90%300,0000300,000
HE Family GRAT
Other
0.60%100,0000100,000
Disclosure Items (6)

Security Title

Ordinary Shares

Issuer Name

CASI Pharmaceuticals, Inc.

Issuer Address

1701-1702, CHINA CENTRAL OFFICE TOWER 1, BEIJING, F4, 100025

On June 16, 2025, Huiying Memorial Foundation purchased 357,644 Ordinary Shares from open market. The total amount of funds for the purchase was $668,371 and Huiying Memorial Foundation used its personal funds to complete the purchase.

The Reporting Persons are filing this Amendment No. 9 to Schedule 13D to report the purchase of 357,644 Ordinary Shares by Huiying Memorial Foundation.

Percentage of Class

See rows (11) and (13) of the cover pages to this Schedule 13D for the aggregate number of Ordinary Shares and percentages of the Ordinary Shares beneficially owned by each Reporting Person. The percentage used in this Schedule 13D is calculated based upon 15,506,348 Ordinary Shares outstanding as of June 20, 2025.

Number of Shares

See rows (7) through (10) of the cover pages to this Schedule 13D for the number of Ordinary Shares as to which each Reporting Person has the sole or shared power to vote or direct the vote and sole or shared power to dispose or to direct the disposition.

Transactions

On June 16, 2025, Huiying Memorial Foundation purchased 357,644 Ordinary Shares from open market at the per share price ranging from US$1.3288 to US$2.088.

Shareholders

No person other than the Reporting Persons is known to have the right to receive, or the power to direct the receipt of dividends from, or proceeds from the sale of, the Shares.

Date of 5% Ownership

Not applicable.

To the best knowledge of the Reporting Persons, except as provided herein and disclosed before, there are no other contracts, arrangements, understandings or relationships (legal or otherwise) between the Reporting Persons and between any of the Reporting Persons and any other person with respect to any securities of the Company, joint ventures, loan or option arrangements, puts or calls, guarantees of profits, divisions of profits or loss, or the giving or withholding of proxies, or a pledge or contingency, the occurrence of which would give another person voting power over the securities of the Company.

Joint Filing Agreement by and among ETP Global Fund LP, Emerging Technology Partners LLC, ETP BioHealth III Fund, LP, HE Family GRAT and Wei-Wu He, Ph.D. dated April 18, 2023.

CASI Pharmaceuticals, Inc. — Schedule 13D | 13D Filings